Pharmaceuticals & Biotech Community

Everest Medicines is trying to grow by bringing new treatments to patients across China and Asia, but tougher approval rules, government price cuts, and rising geopolitical frictions could slow launches and squeeze profits. At the same time, a few key products and a broader pipeline could still surprise on the upside, making it worth weighing how much of the growth story is already built in.Read more

Sichuan Kelun-Biotech is riding a wave in cancer care where targeted “drug-plus-antibody” medicines are becoming more common, and its growing pipeline and overseas partners could turn today’s research bets into tomorrow’s launches and royalty income. The catch is that a lot hinges on big late-stage trials and the company’s ability to shift from partner-funded work to selling more of its own medicines at home and abroad.Read more

Ascentage Pharma could unlock much bigger markets if its Takeda partnership and late-stage trials turn its lead cancer drugs into global products, while wider insurance coverage in China helps more patients access them. The catch is that the business still leans heavily on one main drug and some one-off payments, so setbacks in trials, competition, or rising research costs could quickly change the story.Read more

Akeso cuts drug prices hard to win wider access in China, but that same move could squeeze profits for years if tighter healthcare budgets keep pushing prices down. The real question is whether strong trial results and global partners can help it keep growing while competition heats up.Read more

Everest Medicines is rolling out newer treatments across China and the wider Asia-Pacific, helped by faster approvals, wider insurance coverage, and local manufacturing that could make it easier to reach more patients. The big catch is that near-term progress depends heavily on one key drug, while pricing pressure, costly development bets, and cross-border tensions could derail the story.Read more

Ascentage’s recent results may look stronger than the core business really is, because a big part comes from one-off partner payments that won’t last. At the same time, tighter drug pricing rules in China and tougher global expansion conditions could squeeze future sales and delay new launches.Read more

Akeso’s cancer drugs are seeing unexpectedly strong early demand, and a wider hospital rollout could push growth ahead of what many expect. But steep price cuts, reliance on a few key medicines, and tough competition could make it harder to turn that momentum into lasting profits.Read more

GenScript is betting that faster drug research and a wave of new cell and gene therapies will push more biotech companies to outsource work, and it’s building automated factories and global sites to meet that demand. But the same forces that could lift growth—cutthroat price competition, big spending on new facilities, and political and tech shifts—could also squeeze profits if the bets don’t pay off.Read more

Everest Medicines is banking on two newly launched treatments to spread quickly through Chinese hospitals, helped by insurance coverage, updated medical guidelines, and local manufacturing that can keep supply steady. The bigger bet is that its next wave of advanced cancer and immune therapies can ride Asia’s aging population—while heavy reliance on China and a small set of partners could still trip up the story.Read more